InnoCan Pharma (TSE:INNO) has released an update.
InnoCan Pharma’s subsidiary, BI Sky Global, has successfully registered its products under the FDA’s MoCRA, guaranteeing its high-quality cosmetic products’ continued sale in the U.S. market. Additionally, InnoCan announced an upcoming private placement aiming to raise up to C$880,000 for corporate purposes, with the potential to increase the offering by 30% for over-allotments.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
